Reproductive management of the transitional mare

Equine Health ◽  
2020 ◽  
Vol 2020 (2) ◽  
pp. 42-47
Author(s):  
Camilla Scott

The mare is a seasonally polyoestrous long-day breeder with a physiological breeding season lasting from April–October in the Northern Hemisphere. The hypothalamic-pituitary-gonadal axis in the mare is subject to a circannual endogenous rhythm that is primarily regulated by day length. Increasing ambient photoperiod in the spring alters the pattern of melatonin secretion. The resulting stimulation of hypothalamic gonadotropin-releasing hormone secretion triggers pituitary follicular stimulating hormone release and follicular growth. Exposure of mares in deep anoestrus to a stimulatory photoperiod remains the most successful method of advancing the first ovulation of the season. The most commonly used lighting regimen is providing a fixed length of 15–16 hours of light exposure and 8–9 hours of dark, with a minimum light intensity in a stable of 100-lux (100–200 watt incandescent bulb). Other methods include using an additional 2.5 hours of light beginning at sunset and a pulse lighting system, providing 1 hour of light, 9.5–10.5 hours after the onset of darkness, during the photosensitive phase. Alternatively, the EquilumeTM light masks provide a unilateral LED light source emitting 50 lux of blue-light directly to the eye during the hours after dusk (until 11 pm). Mares that have not been maintained under lights, or that have been exposed to ineffective light therapy, may require therapeutic hormonal intervention to advance the onset of the first ovulation of the season. Many hormone protocols involving progestins, GnRH, dopamine agonists and recombinant luteinising hormone/follicle stimulating hormone have been studied with variable results. Therapy is typically more effective when started either in late transitional mares or following a period of stimulatory artificial photoperiod.

UK-Vet Equine ◽  
2020 ◽  
Vol 4 (2) ◽  
pp. 42-47
Author(s):  
Camilla Scott

The mare is a seasonally polyoestrous long-day breeder with a physiological breeding season lasting from April–October in the Northern Hemisphere. The hypothalamic-pituitary-gonadal axis in the mare is subject to a circannual endogenous rhythm that is primarily regulated by day length. Increasing ambient photoperiod in the spring alters the pattern of melatonin secretion. The resulting stimulation of hypothalamic gonadotropin-releasing hormone secretion triggers pituitary follicular stimulating hormone release and follicular growth. Exposure of mares in deep anoestrus to a stimulatory photoperiod remains the most successful method of advancing the first ovulation of the season. The most commonly used lighting regimen is providing a fixed length of 15–16 hours of light exposure and 8–9 hours of dark, with a minimum light intensity in a stable of 100-lux (100–200 watt incandescent bulb). Other methods include using an additional 2.5 hours of light beginning at sunset and a pulse lighting system, providing 1 hour of light, 9.5–10.5 hours after the onset of darkness, during the photosensitive phase. Alternatively, the EquilumeTM light masks provide a unilateral LED light source emitting 50 lux of blue-light directly to the eye during the hours after dusk (until 11 pm). Mares that have not been maintained under lights, or that have been exposed to ineffective light therapy, may require therapeutic hormonal intervention to advance the onset of the first ovulation of the season. Many hormone protocols involving progestins, GnRH, dopamine agonists and recombinant luteinising hormone/follicle stimulating hormone have been studied with variable results. Therapy is typically more effective when started either in late transitional mares or following a period of stimulatory artificial photoperiod.


Animals ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 1134
Author(s):  
Hao-Qi Wang ◽  
Wei-Di Zhang ◽  
Bao Yuan ◽  
Jia-Bao Zhang

Mammalian reproduction is mainly driven and regulated by the hypothalamic-pituitary-gonadal (HPG) axis. Follicle-stimulating hormone (FSH), which is synthesized and secreted by the anterior pituitary gland, is a key regulator that ultimately affects animal fertility. As a dimeric glycoprotein hormone, the biological specificity of FSH is mainly determined by the β subunit. As research techniques are being continuously innovated, studies are exploring the underlying molecular mechanism regulating the secretion of mammalian FSH. This article will review the current knowledge on the molecular mechanisms and signaling pathways systematically regulating FSH synthesis and will present the latest hypothesis about the nuclear cross-talk among the various endocrine-induced pathways for transcriptional regulation of the FSH β subunit. This article will provide novel ideas and potential targets for the improved use of FSH in livestock breeding and therapeutic development.


Life Sciences ◽  
1985 ◽  
Vol 36 (9) ◽  
pp. 889-899 ◽  
Author(s):  
Henry M. Jones ◽  
Constance L. Wood ◽  
Michael E. Rush

1995 ◽  
Vol 132 (3) ◽  
pp. 357-362 ◽  
Author(s):  
M Tena-Sempere ◽  
L Pinilla ◽  
E Aguilar

Tena-Sempere M, Pinilla L, Aguilar E. Orchidectomy selectively increases follicle-stimulating hormone secretion in gonadotropin-releasing hormone agonist-treated male rats. Eur J Endocrinol 1995;132: 357–62. ISSN 0804–4643 The pituitary component of the feedback mechanisms exerted by testicular factors on gonadotropin secretion was analyzed in adult male rats treated with a potent gonadotropin-releasing hormone (GnRH) antagonist. In order to discriminate between androgens and testicular peptides, groups of males were orchidectomized (to eliminate androgens and non-androgenic testicular factors) or injected with ethylene dimethane sulfonate (EDS), a selective toxin for Leydig cells (to eliminate selectively androgens) and treated for 15 days with vehicle or the GnRH antagonist Ac-d-pClPhe-d-pClPhe-d-TrpSer-Tyr-d-Arg-Leu-Arg-Pro-d-Ala-NH2CH3COOH (Org.30276, 5 mg/kg/72 hours). Serum concentrations of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were measured 7 and 14 days after the beginning of treatment. We found that: in males treated with GnRH antagonist, orchidectomy or EDS treatment did not induce any increase in LH secretion; and orchidectomy, but not EDS treatment, increased FSH secretion in GnRH-treated males. The present results show that negative feedback of testicular factors on LH secretion is mediated completely through changes in GnRH actions. In contrast, a part of the inhibitory action of the testis on FSH secretion is exerted directly at the pituitary level. It can be hypothesized that non-Leydig cell testicular factor(s) inputs at different levels of the hypothalamic–pituitary axis in controlling LH and FSH secretion. Manuel Tena-Sempere, Department of Physiology, Faculty of Medicine, University of Córdoba, 14004 Córdoba, Spain


Author(s):  
H.W.G. BAKER ◽  
W.J. BREMNER ◽  
H.G. BURGER ◽  
D.M. DE KRETSER ◽  
AUSMA DULMANIS ◽  
...  

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Tino Michelle Tsikirai ◽  
Francisco Ramirez ◽  
Neil Nedley

Abstract Objective This study documents the effects that light and exercise therapy have in women experiencing premenstrual syndrome (PMS). Design Methods Study participants were fertile-aged females that were involved in a non-profit community depression and anxiety education program. Participants met in once a week and were taught about the effects of healthful cooking, regular exercise (at least 40 minutes of exercise five times a week), bright light exposure (20 - 40 minutes of exposure) from the sun or from a light box, and other healthy behaviors on their mental health. All participants took a 75-item questionnaire at the beginning and the end of the program to establish a baseline and measure changes in depression levels. The questionnaire measured depression level based on DSM-5 [The Diagnostic and Statistical Manual of Mental Disorders Volume 5] criteria. Participants were asked to provide their demographical information and patient history, including information about premenstrual syndrome. Depression was classified into 4 categories as none (0-6), mild (7-10), moderate (11-19) or severe (20 or more). Results From 1968 females 803 reported suffering from PMS mean age 38.8, SD 8.9. Baseline mean depression was 15.3, SD 15.3, median 16 and mode of 18. At the end from the 803, 280 established exercise and light therapy, that group had a depression average of 6.2 (SD 5.5), median 5, mode 0 and 83 (29.6%) of them reported no longer PMS symptoms. At the end those 125 did not established the exercise and light therapy had a depression average of 7.7 (SD 5.5), median 7 and mode 8 and 34 (27.2%) no longer reported PMS symptoms. Conclusions Women experiencing PMS exhibit improved mental health as a result of light and exercise therapy. Lifestyle intervention for maladies related to this syndrome may be an effective alternative to pharmaceutical medications.


Sign in / Sign up

Export Citation Format

Share Document